Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)

被引：0
|
作者：
Kohler, S. [1 ]
Kaspers, S. [1 ]
Salsali, A. [2 ]
Zeller, C. [3 ]
Woerle, H. -J. [1 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[2] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
49
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [1] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [2] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [3] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
    Lund, S.
    Solimando, F.
    Kohler, S.
    Zeller, C.
    Kaspers, S.
    DIABETOLOGIA, 2016, 59 : S26 - S27
  • [4] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S325 - S326
  • [5] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael W.
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [6] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
    Roden, Michael
    Weng, Jianping
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A69 - A69
  • [7] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [8] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [9] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher S.
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A273 - A273
  • [10] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Vedel, Anita
    Roux, Christiansen Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A280 - A280
12345